BP Figure 7: AZD1656 increases liver steatosis in the Gckrdel/wt mouse.

Gckrwt/wt and Gckrdel/wt were fed on a HFD without (open bar) or with (shaded) 3 mg/kg AZD1656 for 16 wk. A) Lowering of blood glucose by AZD1656 after 4 wk and 14 wk in Gckrwt/wt and Gckrdel/wt mice. B) Higher plasma insulin by Gckrdel/wt genotype at 4 wk and 14 wk. C) Impaired glucose tolerance in AZD1656-treated Gckrdel/wt mice. D) Increased plasma FFA by AZD1656 treatment in Gckrdel/wt mice. E) Increased plasma cholesterol by AZD1656 treatment in Gckrdel/wt mice. F) Increased liver / body weight ratio by AZD1656 treatment in Gckrdel/wt mice. G) Increased liver triglyceride by AZD1656 treatment in Gckrdel/wt mice. H) Higher hepatocyte steatosis, microvesicular steatosis and fibrosis scores by AZD1656 treatment in Gckrdel/wt mice. I) Representative haematoxylin and eosin (H&E) and Sirius red fast green (SRFG) images for histopathology scores, scale bar 200µm. J) Liver mRNA levels (RT-qPCR) for the genes indicated expressed as a ratio to RplpO showing increased expression of Fgf21, Cidea and Cidec by AZD1656 treatment in the Gckrdel/wt mice: n= 10 and 11 for Gckrwt/wt (-/+) and n= 6 and 10 for Gckrdel/wt (-/+) *P < 0.05 effect of AZD1656; #P < 0.05 effect of genotype.

Gckrwt/wt 和 Gckrdel/wt 线粒体在未加（开放栏）或加（遮蔽）3 mg/kg AZD1656 的高脂肪饮食（HFD）下饲养16周。A）AZD1656在Gckrwt/wt和Gckrdel/wt小鼠中，在第4周和第14周降低血糖。B）Gckrdel/wt基因型在4周和14周时血浆胰岛素水平更高。C）AZD1656处理的Gckrdel/wt小鼠葡萄糖耐量受损。D）AZD1656治疗使Gckrdel/wt小鼠血浆游离脂肪酸（FFA）水平升高。E）AZD1656治疗使Gckrdel/wt小鼠血浆胆固醇水平升高。F）AZD1656治疗使Gckrdel/wt小鼠的肝脏/体重比增加。G）AZD1656治疗使Gckrdel/wt小鼠肝脏甘油三酯水平升高。H）AZD1656治疗使Gckrdel/wt小鼠的肝细胞脂肪变性、微小泡状脂肪变性和纤维化评分升高。I）代表性苏木精和伊红（H&E）及伊红S快速绿色（SRFG）图像用于组织病理学评分，比例尺为200µm。J）肝脏mRNA水平（RT-qPCR）用于所指示的基因，以RplpO为参照，显示AZD1656处理使Gckrdel/wt小鼠中的Fgf21、Cidea和Cidec表达增加：Gckrwt/wt（-/-）组n=10和11，Gckrdel/wt（-/-）组n=6和10。*P < 0.05表示AZD1656的影响；#P < 0.05表示基因型的影响。